Orion invests $415.6M in LegoChem Biosciences to lead in next-gen anticancer drugs with ADC technology

Johnson & Johnson acquires Ambrx for $2 Billion to boost next-gen cancer therapies

LegoChem secures $411M from confectionery firm in ADC advancement

At JPM24, Novartis CEO discusses resisting the ADC field trend among cancer players